STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly's gene-editing therapy has shown promising results in a Phase 1 trial, reducing cholesterol levels by 62% without serious adverse effects, as the company plans to advance to Phase 2 trials. Additionally, Lilly has announced acquisitions of three vaccine developers for up to $4 billion, expanding its focus on infectious diseases.
Eli Lilly's recent Phase 1 trial results for a gene-editing therapy that reduced cholesterol levels by 62% without serious adverse events signal a promising development in precision medicine and gene therapy. With plans to advance to Phase 2 trials, this underscores a significant opportunity for stakeholders in healthtech and biotech sectors to monitor advancements in gene-editing solutions, particularly those addressing widespread conditions like high cholesterol.